Effects of ensaculin on dopamine metabolite levels and K(+)-induced glutamate release.
In vivo microdialysis with the new antidementia compound ensaculin was performed in freely moving rats to study the alterations in dopaminergic and glutamatergic neurotransmission. Ensaculin (0.1 and 1 mg/kg i.p.) significantly increased extracellular levels of the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Furthermore, ensaculin (1 mg/kg i.p.) showed a non-significant tendency to reduce the K(+)-induced glutamate release. The data suggest that ensaculin may have moderate D(2) antagonistic properties. Thus, besides its possible role as a cognitive enhancer, ensaculin may also have moderate antipsychotic properties.
Teismann
P
P
Institute of Pharmacology and Toxicology, Faculty of Pharmacy, University of Marburg, Ketzerbach 63, D-35032, Marburg, Germany.
Ferger
B
B
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D018698:Glutamic Acid / Q000187:drug effects* / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D017551:Microdialysis; D010879:Piperazines / Q000494:pharmacology*; D011188:Potassium / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D001578:Benzopyrans; D010879:Piperazines; D015102:3,4-Dihydroxyphenylacetic Acid; D018698:Glutamic Acid; C112452:Ensaculin; D011188:Potassium; D004298:Dopamine; D006719:Homovanillic Acid